Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $15.3333.

Several research firms have weighed in on CABA. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of Cabaletta Bio in a research report on Monday, May 4th. Jefferies Financial Group restated a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Wall Street Zen downgraded Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Wells Fargo & Company dropped their price target on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday, August 14th.

Get Cabaletta Bio alerts:

Read Our Latest Stock Analysis on CABA

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CABA. Kestra Advisory Services LLC acquired a new stake in shares of Cabaletta Bio during the 1st quarter valued at $32,000. SummitTX Capital L.P. acquired a new position in shares of Cabaletta Bio in the first quarter worth $34,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Cabaletta Bio during the fourth quarter worth $34,000. Legal & General Group Plc purchased a new stake in shares of Cabaletta Bio during the second quarter worth $34,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Cabaletta Bio in the fourth quarter valued at about $38,000.

Cabaletta Bio Trading Down 1.9%

NASDAQ CABA opened at $3.13 on Friday. The stock’s 50-day moving average price is $2.88 and its two-hundred day moving average price is $3.07. The company has a market cap of $530.66 million, a PE ratio of -1.99 and a beta of 3.30. Cabaletta Bio has a 1 year low of $1.40 and a 1 year high of $4.23.

Cabaletta Bio (NASDAQ:CABA – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Research analysts forecast that Cabaletta Bio will post -1.34 EPS for the current fiscal year.

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

Featured Stories

• Five stocks we like better than Cabaletta Bio
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.